| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HAYWARD, Calif.—DNA sequencing specialist Solexa announced it has reached an agreement with New England Biolabs (NEB) to provide Solexa with key enzymes and reagents for its Genome Analysis System. NEB will also manufacture Solexa's proprietary sequencing-by-synthesis polymerase.
 
"Having a strong relationship with a leader in next-generation sequencing technologies is of great value to NEB, allowing us to contribute to an area which has the potential to change both biological research and the practice of human medicine," stated Dr. Fiona Stewart, NEB business development manager.
 
The agreement follows closely on the heels of a similar collaboration between Solexa and Invitrogen that will see the consumables company supply Solexa with reagents for its sequencing system.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue